The managment of MPS disorders requires a multidisciplinary evaluation for multi-organ involvement. The new therapeutic approaches to MPS have drastically changed the natural history of disease. Transplantation of hematopoietic stem cells from bone marrow or umbilical cord can achieve significant benefits. The clinical success of this therapeutic approach depends on age, stage of disease, type of donor and ability to achieve stable engraftment without the development of graft-vshost disease [18, 20] . In early stages of disease, enzyme replacement therapy can benefit musculoskeletal symptoms and lung function [21] [22] [23] . This therapy, however, does not cross the blood-brain barrier and has not shown neurocognitive benefit.
In conclusion, the goal is the prompt identification of MPS disorders since an early diagnosis could allow early treatment: in this regard, particular attention should be given to an accurate differential diagnosis with chronic inflammatory arthropathies.
